Portfolio of Single Strain Live Biotherapeutic Products (SS-LBP)

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024 Gut-Brain Axis

Alzheimer’s Disease

ADS024 is a non-engrafting SS-LBP with anti-inflammatory properties. Oral administration of ADS024 has been shown to be effective in a model of Alzheimer’s Disease and multiple other animal models of neuroinflammatory diseases suggesting an impact on a common underlying pathology. Agonism of LPAR3, a G-protein coupled receptor, has been shown to be the main mechanism of action of ADS024. ADS024 presents promising therapeutic potential for the treatment of a wide range of neuroinflammatory and neurodegenerative diseases, including Alzheimer’s disease.

Publications

Featured Poster

ADS024 Attenuates Striatal Dopamine Loss and Restores Movement in Animal Models of Parkinson’s Disease

Acton S and Chesnel L.

LPAR3: a shared target for neurodegenerative diseases?

Neural Regeneration Research. ():10.4103/NRR.NRR-D-24-01024, 2024 Dec 7.

Acton S, O’Donnell MM, Periyasamy K, Dixit B, Eishingdrelo H, Hill C, Paul Ross R, Chesnel L.

LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease models.

Brain Behav Immun. 2024 Aug 13:S0889-1591(24)00547-6.

Irwin S, Chupina Estrada A, Nelson B, Bullock A, Limketkai B, Ho W, Acton S, Chesnel L, Koon HW.

ADS024, a single-strain live biotherapeutic product of Bacillus velezensis alleviates dextran sulfate-mediated colitis in mice, protects human colonic epithelial cells against apoptosis, and maintains epithelial barrier function.

Front Microbiol. 2024 Jan 10;14:1284083.

Murphy CK, O’Donnell MM, Hegarty JW, Schulz S, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L.

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo.

World J Gastrointest Pathophysiol. 2023 Aug 24;14(4):71-85.

Xie Y, Chupina Estrada A, Nelson B, Feng H, Pothoulakis C, Chesnel L, Koon HW.

ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis.

Front Microbiol. 2023 Jan 10;13:1072534.

O’Donnell MM, Hegarty JW, Healy B, Schulz S, Walsh CJ, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L.

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities.

Sci Rep. 2022 Jun 3;12(1):9283.

Acton, S., Meilin, S., Schulman, Y., Aran, J., Periyasamy, K., and L. Chesnel.

ADS024, a single strain live biotherapeutic product, attenuates MOG-EAE induced clinical symptoms in mice and zebrafish.

Multiple Sclerosis Journal Volume 29, Issue 3_suppl: MSMilan 2023 Oct 2023 P1459/415 ePoster 2023 SAGE Publications.

L. Chesnel and S. Acton (Concord, USA)

ADS024 attenuates striatal dopamine loss and restores movement in animal models of Parkinson’s disease [abstract].

Mov Disord. 2022; 37 (suppl 2).